131 related articles for article (PubMed ID: 33256013)
1. One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [
Kanellopoulos P; Kaloudi A; Rouchota M; Loudos G; de Jong M; Krenning EP; Nock BA; Maina T
Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33256013
[TBL] [Abstract][Full Text] [Related]
2. (99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice.
Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
Nucl Med Biol; 2016 Jun; 43(6):347-54. PubMed ID: 27260775
[TBL] [Abstract][Full Text] [Related]
3. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the Profile of [
Kanellopoulos P; Nock BA; Krenning EP; Maina T
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114537
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology.
Kanellopoulos P; Mattsson A; Abouzayed A; Obeid K; Nock BA; Tolmachev V; Maina T; Orlova A
EJNMMI Radiopharm Chem; 2024 Feb; 9(1):13. PubMed ID: 38366299
[TBL] [Abstract][Full Text] [Related]
7. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Maina T; Kaloudi A; Valverde IE; Mindt TL; Nock BA
Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
[TBL] [Abstract][Full Text] [Related]
8. [
Kanellopoulos P; Lymperis E; Kaloudi A; de Jong M; Krenning EP; Nock BA; Maina T
Molecules; 2020 Jul; 25(15):. PubMed ID: 32731473
[No Abstract] [Full Text] [Related]
9. 99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation.
Marsouvanidis PJ; Maina T; Sallegger W; Krenning EP; de Jong M; Nock BA
J Nucl Med; 2013 Oct; 54(10):1797-803. PubMed ID: 24009275
[TBL] [Abstract][Full Text] [Related]
10. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
[TBL] [Abstract][Full Text] [Related]
11. Localization of
Kaloudi A; Lymperis E; Kanellopoulos P; Waser B; de Jong M; Krenning EP; Reubi JC; Nock BA; Maina T
Pharmaceuticals (Basel); 2019 Mar; 12(1):. PubMed ID: 30897789
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of
Abouzayed A; Rinne SS; Sabahnoo H; Sörensen J; Chernov V; Tolmachev V; Orlova A
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33573232
[TBL] [Abstract][Full Text] [Related]
13. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
14. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
Lymperis E; Kaloudi A; Sallegger W; Bakker IL; Krenning EP; de Jong M; Maina T; Nock BA
Bioconjug Chem; 2018 May; 29(5):1774-1784. PubMed ID: 29664606
[TBL] [Abstract][Full Text] [Related]
15. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.
Kaloudi A; Nock BA; Lymperis E; Sallegger W; Krenning EP; de Jong M; Maina T
Nucl Med Biol; 2015 Nov; 42(11):824-32. PubMed ID: 26300210
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
[TBL] [Abstract][Full Text] [Related]
17. Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation.
Kaloudi A; Nock BA; Lymperis E; Valkema R; Krenning EP; de Jong M; Maina T
EJNMMI Res; 2016 Dec; 6(1):15. PubMed ID: 26882895
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
